KALA | tickerfilter.com

Fundamental analysis

12%

Profitability 8%

Dept financing 14%

Liquidity 75%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

5.68%

1 Month

-26.49%

3 Months

-57.70%

6 Months

-98.27%

1 Year

-95.74%

2 Year

-96.24%

Key data

Stock price

$0.29

P/E Ratio

0.00

DAY RANGE

$0.25 - $0.32

EPS

-$6.12

52 WEEK RANGE

$0.23 - $20.60

52 WEEK CHANGE

-$95.77

MARKET CAP

10.742 M

YIELD

N/A

SHARES OUTSTANDING

8.210 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-13-2025

BETA

0.71

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,385,509

AVERAGE 30 VOLUME

$803,678

Company detail

CEO: Mark T. Iwicki
Region: US
Website: kalarx.com
Employees: 30
IPO year: 2017

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Kala Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid.

KALA - KALA BIO, Inc.